Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000165917 | SCV000216672 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-04-07 | criteria provided, single submitter | clinical testing | The p.L565V variant (also known as c.1693T>G), located in coding exon 11 of the PMS2 gene, results from a T to G substitution at nucleotide position 1693. The leucine at codon 565 is replaced by valine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Gene |
RCV000480451 | SCV000565416 | uncertain significance | not provided | 2022-11-21 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
| Invitae | RCV000531904 | SCV000625552 | uncertain significance | Hereditary nonpolyposis colorectal neoplasms | 2023-07-17 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 565 of the PMS2 protein (p.Leu565Val). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PMS2-related conditions. ClinVar contains an entry for this variant (Variation ID: 186338). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PMS2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Knight Diagnostic Laboratories, |
RCV000415672 | SCV000493781 | uncertain significance | Lynch syndrome 4 | 2015-08-13 | no assertion criteria provided | clinical testing |